CD19 and neoplasm: These findings support the hypothesis that the administration of cetuximab might result in the recovery of the B cell compartment in patients who have undergone CD19-based CAR T cell therapy and experienced prolonged persistence of CD19-redirected CAR T cells, B cell aplasia, and complete tumor regression (113).